Five things for pharma marketers to know for Monday, March 2, 2026 - MMM Online

The Food and Drug Administration will offer bonuses to speedy drug reviewers. Agency reviewers who complete their work on specific drugs ahead of schedule could receive performance bonuses, provided their review is also thorough. In announcing the pilot program, FDA Commissioner Marty Makary said to agency staffers, “If you don’t like [the program], we can get rid of it, but usually everybody loves money.” (Associated Press)

Generate Biomedicines raised a $400 million IPO as its CEO says the era of AI-designed drugs is coming soon. This marked one of the largest biotech listing debuts in multiple years and the first startup from Flagship’s sprawling portfolio to IPO in four-and-a-half years. (Boston Business Journal)

Novartis and Takeda agreed to enter the third round of Medicare drug price negotiations. Novartis confirmed to Endpoints News this week that it will negotiate prices for its drugs Kisqali and Cosentyx. (Endpoints News)

The Department of Justice backed AbbVie in its 340B battle in Colorado. AbbVie and a slew of other drugmakers continue to challenge the distribution of discounted 340B drugs. The Justice Department’s recent amicus brief provides more insight into the Trump administration’s view on contentious contract pharmacy use. (Bloomberg)

Videos of Secretary Robert F. Kennedy Jr., who has cultivated a passionate following on certain issues thanks to his Make America Healthy Again movement, have been posted to official channels of the Department of Health and Human Services. While President Trump is known for his in-your-face embrace of social media, Kennedy’s tactics stand out, even among past HHS secretaries with political ambitions. (STAT News)

To read last Friday’s Five things for pharma marketers to know, click here.